Latham Advises Norgine on Acquisition of Theravia

Latham & Watkins has advised Norgine, a leading European specialty pharmaceutical company, on a definitive agreement with Theravia, an international pharmaceutical company specializing in cutting-edge treatments for patients with rare and debilitating conditions, under which Norgine will acquire Theravia from Mérieux Equity Partners. The acquisition represents a meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines.

The Latham team was led by London partner Robbie McLaren and Paris partner Olivier du Mottay, with associates Jacek Urban and Wooseong Choi. Additional advice on healthcare matters was provided by Paris partner Eveline Van Keymeulen, with associates Jeanne Fabre, Oliver Mobasser, Luke Nauth, and Alexis Vaujany; on data and technology matters by associate Daniel Martel; on competition law due diligence matters by associates Constance Dobelmann and Agnès de Fortanier; on banking matters by associate Natacha Adjoba Enoh; on sanctions matters by London partner Robert Price, with associates Thomas Lane and Hana Ladhari; on employment matters by Paris partner Matthias Rubner, with associate Yanis Gaoua; and on data privacy matters by associate Charlotte Guérin.